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Abstract
Background: The aim of the present study was to evaluate the survival, efficacy and safety of a modified RADPLAT-like
protocol using carboplatin instead of cisplatin.
Methods: Fifty-six patients with primary head and neck squamous cell carcinoma received 4 cycles of intra-arterial
carboplatin (350 mg/m2 per cycle every 2 weeks), with concurrent three-dimensional conformal radiation therapy.
Results: Two major and 4 minor complications were observed. Forty-five of the 56 patients (80%) completed the
protocol, while 11 (20%) patients had to discontinue the intra-arterial infusions due to the occurrence of severe
haematological toxicity, but were able to complete radiotherapy.
Forty-four (98%) of the 45 patients who completed the protocol and 10 (91%) of the 11 who did not, were free of disease
at the end of the treatment, for a comprehensive 96% of CR overall.
After a median 23.55 months (range: 2 to 58 months) of follow-up, 40 patients (71%) are alive and disease-free, 1 (2%)
is alive but affected by disease and 15 (27%) have died of the disease or other causes.
Conclusion: Intra-arterial carboplatin administration with concurrent three-dimensional conformal radiation therapy
seems to be a promising alternative to RADPLAT in the treatment of advanced head and neck tumours. Haematological
and non-haematological toxicities are virtually similar, but carboplatin has the advantage in that it is not nephrotoxic and
can be used at very high doses without any significant increase in the extent of side effects.
Published: 4 September 2009
BMC Cancer 2009, 9:313 doi:10.1186/1471-2407-9-313
Received: 4 December 2008
Accepted: 4 September 2009
This article is available from: http://www.biomedcentral.com/1471-2407/9/313
© 2009 Bertino et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Cancer 2009, 9:313 http://www.biomedcentral.com/1471-2407/9/313
Page 2 of 10
(page number not for citation purposes)
Background
During the past decade, chemoradiation has become the
most important treatment option for locally advanced
head and neck squamous cell carcinoma (HNSCC). In
particular, the combination of concurrent chemotherapy
and three-dimensional conformal radiotherapy (3D CRT)
appears to be more potent than sequential chemoradia-
tion therapy in terms of local control of the disease and
improvement of overall survival [1,2]. To overcome the
potential chemoradioresistance of head head and neck
tumours, supradose infusions of cisplatin via superselec-
tive intra-arterial chemotherapy were introduced [3-5].
Thanks to the convincing results of Robbins' RADPLAT
protocol [5], many other institutions have used RADPLAT
or RADPLAT mimicking protocols for the treatment of
HNSCC, with a high success rate [6-8].
To overcome the main cisplatin-related toxicities, i.e. kid-
ney function impairment and nausea/vomiting [9], many
authors have replaced cisplatin with carboplatin, which
has proven to be as effective as cisplatin in sequential or
concurrent chemoradiation protocols, but better toler-
ated; indeed, carboplatin is virtually non-nephrotoxic and
does not cause such severe nausea and vomiting [10-12].
For this reason, we first applied Robbins' super-selective
intra-arterial administration technique to infuse carbopl-
atin in a neo-adjuvant treatment protocol with very
encouraging results [13-15].
The low rate of toxic effects observed in our first protocol
[15] led us to initiate a phase II protocol combining 3D
CRT with concomitant intra-arterial carboplatin adminis-
tration to treat advanced HNSCC.
The aim of this study was to evaluate survival, efficacy and
safety of our modified RADPLAT-like protocol on a single
group of patients affected by advanced HNSCCC.
Methods
Patient characteristics
Fifty-six patients (46 men and 10 women), aged from 38
to 74 years (mean 58,4, median 59 years), with previously
untreated squamous cell carcinoma (SCC) of the upper
aerodigestive tract were treated between March 2003 and
February 2008. The sites and stages of the tumor, classi-
fied according to the UICC/AICC TNM [16], are reported
in table 1 and table 2. The stage II patients in table 2 were
submitted to this protocol owing to general conditions
that contraindicated surgery or because they refused to
undergo surgery. Patients were required to sign an
informed consent form after the Ethical Committee of our
Institution formally approved the study.
Pre-treatment evaluation
Patients underwent a complete clinical and laboratory
examination including measurement of haematological,
hepatic and renal parameters, as well as general metabolic
functions, chest radiography and electrocardiography.
The disease was staged by physical and endoscopic exam-
ination, biopsy with histopathological and immunohisto-
chemical examination, CT scan of the head and neck and
of the thorax, MRI (when appropriate) and PET.
Inclusion criteria for the treatment protocol were primary
untreated SCC, absence of distant metastases, age < 74
years, no haematological or metabolic contraindications
against chemotherapy.
Table 1: Site of the tumor
Tumor site N.
Oral cavity 20
Hypopharynx 3
Oropharynx 32
Larynx 1
Total 56
Table 2: Stage of the tumor
Stage TNM N.
II T2N0M0 12
III T2N1M0 6
T3N0M0 9
T3N1M0 4
IVA T1N2aM0 1
T1N2bM0 3
T2N2aM0 4
T2N2bM0 1
T3N2aM0 1
T3N2bM0 1
T3N2cM0 2
T4N0M0 3
T4N1M0 2
T4N2aM0 3
T4N2bM0 1
T4N2cM0 2
IVB T2N3M0 1
Total 56BMC Cancer 2009, 9:313 http://www.biomedcentral.com/1471-2407/9/313
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Treatment protocol
Figure 1 summarizes the timing of the treatment protocol.
The planned dose of carboplatin per cycle was 350 mg/m2
with a maximum amount of 1,4 g/m2 given in 4 cycles,
every 2 weeks. No pharmacokynetic analyses were per-
formed to select the dose of the drug, but it was chosen
according to our previous experience of induction intra-
arterial chemotherapy [15]. Carboplatin was adminis-
tered intra-arterially (i.a.), dissolved in 80 mL of 0,9%
saline and infused over 15-20 min by a battery-operated
pump (Medrad Mark 5 Plus) with an infusion velocity of
4-6 mL/min. An angiographic catheter (Glidecath Radico-
focus 5F Terumo) was introduced percutaneously under
local anesthesia (10 mL of 2% lidocaine solution) into the
common femoral artery, according to the Seldinger tech-
nique. The catheter tip was placed in the external carotid
artery, under radiographic control. Diagnostic transfemo-
ral carotid arteriography was performed and the most suit-
able branch of the artery, providing the main blood
supply to the tumour, was selectively catheterised. The
catheter was removed immediately after the infusion. A
simultaneous intravenous (i.v.) infusion of 250 mL of
0,9% saline was administered. Dexamethasone (4 mg)
and ondansetron (1 g) dissolved in 100 mL of 0,9% saline
were administered i.v. 1 hour before the infusion.
While undergoing chemotherapy, patients also received
concomitant 3D CRT with conventional fractionation
(1,8 - 2 Gy per fraction, five days per week). The total dose
was 66 - 74 Gy for PTVI (Planning Target Volume: volume
planned to receive prescribed dose, according to ICRU
Report 50 and 62) [17,18] including tumour site and clin-
ically positive nodes, and 50-60 Gy for PTVII, including
tumour site and all cervical lymph nodes (positives and
negatives).
When the volume including tumor and positive nodes
resulted too large to receive 64-72 Gy (9 cases), we
defined three PTV: PTV I including tumor site, PTV II
including tumour site and positive nodes, PTV III includ-
ing tumor site and all cervical lymph nodes (positives and
negatives). In these cases we had 64-74 Gy for PTV I, 56-
66 Gy for PTV II, 50-60 Gy for PTV III.
All patients underwent planning CT in a supine position
with a thermoplastic mask as a custom immobilisation
device. In all slices acquired planning target volumes and
organs at risk (spinal cord, parotid glands, mandibula)
were contoured. Dose-volume histograms (DVH) were
evaluated by the radiation oncologist and physicians and
only dose inhomogenities between 90% and 110% out of
prescribed dose were accepted. All patients were irradiated
on a linear accelerator, with Cerrobend blocks or multi-
leaf collimators. All treatment fields were verified before
starting therapy.
Treatment evaluation
Haematological and non-haematological toxicities were
evaluated according to NCI-CTCAE v3.0 [19] 24 hours
before and after each course of i.a. chemotherapy.
Response to therapy was assessed at the end of the treat-
ment protocol by physical examination and endoscopy,
while CT scan and/or MRI were performed at 3, 6, and
every 12 months after the end of therapy; a biopsy was
performed if recurrence was suspected. A complete
response (CR) was defined as the complete disappearance
of all demonstrable lesions. A partial response (PR) was
defined as a decrease of 50% or more in the sum of the
products of the largest perpendicular diameters of all
measurable lesions. No response (NR) was defined as a
regression of < 50% in total tumour size or as stable or
progressive disease.
Statistical analysis
The first end point was overall survival. Survival was
measured from the date of the first infusion to the date of
death or the date when the patient was last known to be
alive. Secondary end points were CR rates, loco-regional
Timing of the treatment protocol Figure 1
Timing of the treatment protocol. SS = Saturday, Sunday; RT = radiotherapy; IAC = intra-arterial chemotherapy.
0           15        30            45       end 
SS SS SS SS SS SS SS SS
     RT     RT    RT          RT        RT      RT    RT       RT  
IAC           IAC      IAC             IAC 
RT           RT       RT             RT BMC Cancer 2009, 9:313 http://www.biomedcentral.com/1471-2407/9/313
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tumour control and disease-free survival. Time to loco-
regional failure was measured from the start of treatment
and the date of disease relapse, the date of disease-related
death, or the date when the patient was last known to be
alive and disease-free. Loco-regional failure, distant
metastases, or disease-related death were all considered
failures for disease-free survival. OS and disease-free sur-
vival rates (with their 95% Confidence Intervals) were
estimated with the Kaplan-Meier method and log rank
tests were used for univariate comparisons between
groups. P values lower than 0.05 were considered signifi-
cant. Data analysis was performed with the STATA statisti-
cal package (release 9.0, 2006, Stata Corporation, College
Station, Texas, USA).
Results
Feasibility
Two hundred and thirteen super-selective transfemoral
intra-arterial infusions of carboplatin were performed.
Two major complications (1 transient ischemic attack
(TIA) and 1 partial necrosis of the tongue) and 4 minor
complications (3 cases of skin rash and 1 neck oedema)
linked to the intra-arterial chemotherapy were observed.
Toxicity
Carboplatin treatment was well-tolerated by the majority
of the patients. In particular, 45 of the 56 patients (80%)
completed the protocol, while 11 (20%) patients had to
discontinue the intra-arterial infusions, but nevertheless
were able to complete radiotherapy.
Table 3 summarizes why the infusions were suspended. In
1 case, the patient decided to interrupt intra-arterial chem-
otherapy while in another case it was suspended due to
the occurrence of bronchopneumonia. In the other 9
cases, chemotherapy was suspended due to the appear-
ance of thrombocytopenia. This was associated with leu-
kopenia and anaemia in 5 of the 9 patients.
Tables 4 and 5 list all cases of haematological and non-
haematological toxicity observed during the treatment
protocol.
Two patients underwent s.c. granulocyte-colony stimulat-
ing factor (G-CSF) administration due to the appearance
of severe leukopenia and 1 patient received erithrocyte
transfusion for severe anaemia all after 3 infusions; 2
patients required tracheotomy due to severe dyspnea; 1
patient was temporarily fed with a nasogastric tube; while
3 other patients were submitted to PEG for severe mucosi-
tis with odynophagia. All the non-haematological com-
plications appeared after 20 days from the beginning of
the treatment protocol
Table 3: Reasons for suspension of intra-arterial chemotherapy.
N. of infusions N. of patients Reasons for suspension
1/4 1 pneumonia
2/4 1 thrombocytopenia (1) leukopenia (4) anaemia (3)
1 thrombocytopenia (4) leukopenia (1) anaemia (1)
3/4 1 Patient's decision
2 thrombocytopenia (1) leukopenia (1)
thrombocytopenia (1) leukopenia (1) anaemia (1)
2 thrombocytopenia (2) leukopenia (1)
thrombocytopenia (2) leukopenia (1) anaemia (1)
2 thrombocytopenia (3) leukopenia (3)
thrombocytopenia (3) leukopenia (2) anaemia (3)
1 thrombocytopenia (4)
Total 11
(n.) = grade of haematological toxicity (NCI-CTCAE v3.0)BMC Cancer 2009, 9:313 http://www.biomedcentral.com/1471-2407/9/313
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Response rate
Figure 2 summarizes the immediate post-treatment
response. Forty-four (98%) of the 45 patients who com-
pleted the protocol and 10 (91%) of the 11 who did not,
were free of disease at the end of the treatment, for a com-
prehensive 96% of CR.
Disease control and survival
No patients were lost to follow-up. Median follow-up
time (25th-75th percentile), measured from the first intra-
arterial carboplatin administration, was 23.55 months
(range: 2 to 58 months).
The 2 NR patients died of the disease after 9 and 21
months from the beginning of the treatment; of the other
54 CR patients, 1 died of broncopneumonia 9 months
after the treatment beginning; 14 recurred after a median
period of 9 months (range 4-19 months). In 5 of these 14
patients disease recurred at the primary site, 2 at the pri-
mary site and on the neck, 1 at the primary site with pul-
monary and bone metasases, 1 on the neck with
pulmonary metasases, 4 presented only distant metasases;
1 patient developed a second primary tumour. All the
patients who presented regional recurrence and/or distant
metastases had clinically positive necks at the beginning
of therapy.
Only 2 of the 5 patients with recurrence at the primary site
were submitted to salvage surgery, both 10 months after
the beginning of the treatment; 1 of them is still alive and
disease free but the other developed disease recurrence 3
years later and died of the disease. One patient with recur-
rence at the primary site is still alive with disease. The
other 9 patients with recurrence were all submitted to sys-
temic chemotherapy (curative or palliative) and died of
disease (Figure 3).
In conclusion, 40 patients (71%) are alive and disease-
free (NED), 1 (2%) is alive with disease (AWD) and 15
(27%) have died of the disease (DWD) or other causes
(DOD).
The percentage of organ preservation was 97,5%, as only
1 of the 40 NED patients underwent salvage surgery at the
tumour site.
The probability of two-year overall survival was 75%
(95% CI: 59% - 85%) (Figure 4). Among the factors influ-
encing survival, gender, N status and recurrence were sta-
tistically significant. In particular, all the patients who
died were male and the presence of a positive neck at the
time of diagnosis and/or recurrence were significantly
negatively correlated with survival (Figure 5 and 6).
Age, tumour site, T-stage, grading and completion of the
treatment showed no effect on survival.
Two-year disease-free survival was 69% (95% CI: 54% -
81%) (Figure 7). In this case, the only factor significantly
influencing the appearance of recurrence was gender, in
fact all the patients who recurred were males.
As regards T and N stage, we observed a higher likelihood
of recurrence for advanced tumours, even if this tendency
was not statistically significant. Other factors such as age,
tumour site, grading and completion of the treatment did
not significantly influence recurrence of the disease.
Discussion
Our study confirmed the evidence that intra-arterial
chemotherapy by superselective transfemoral infusion of
high doses of platinum compounds with concomitant 3D
Table 4: Acute haematological toxicity (NCI-CTCAE v3.0)
Grade 1
(n.v. - 10 g/dl)
Grade 2
(<10 - 8 g/dl)
Grade 3
(< 8 g/dl - 6,5 g/dl)
Grade 4
(< 6,5 g/dl)
Anaemia* 20/56
(35%)
6/56
(11%)
3/56
(5%)
0/56
-
Grade 1
(n.v. - 1,5 × 103/μl)
Grade 2
(<1,5 - 1 × 103/μl)
Grade 3
(< 1 - 0,5 × 103/μl)
Grade 4
(< 0,5 × 103/μl)
Leukopenia* 14/56
(25%)
10/56
(18%)
8/56
(14%)
1/56
(2%)
Grade 1
(n.v. - 75 × 103/μl)
Grade 2
(< 75 - 50 × 103/μl)
Grade 3
(< 50 - 25 × 103/μl)
Grade 4
(< 25 × 103/μl)
Thrombocytopenia* 10/56
(18%)
6/56
(11%)
5/56
(9%)
2/56
(3%)
*worst toxicity observedBMC Cancer 2009, 9:313 http://www.biomedcentral.com/1471-2407/9/313
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Table 5: Non-haematological acute toxicity (NCI-CTCAE v3.0) *worst toxicity observed
Grade 1
(erithema)
Grade 2
(ulcers or 
pseudomembranes)
Grade 3
(confluent ulcers)
Grade 4
(necrosis)
Stomatitis* 15/56
(27%)
12/56
(21%)
4/56
(7%)
1/56
(2%)
Grade 1
(symptomatic, regular food 
intake)
Grade 2
(impaired swallowing; i.v. 
fluids)
Grade 3
(enteral/parenteral nutrition)
Grade 4
(life-treatening 
consequences)
Dysphagia* 20/56
(36%)
10/56
(18%)
4/56
(7%)
0/56
-
Grade 1
(light erithema or 
desquamation)
Grade 2
(moderate erithema or 
desquamation with oedema)
Grade 3
(erithema or desquamation 
with induced bleeding)
Grade 4
(necrosis with spontaneous 
bleeding)
Dermatitis* 14/56
(25%)
3/56
(5%)
3/56
(5%)
0/56
-
Grade 1
(asymptomatic)
Grade 2
(symptomatic without 
respiratory distress)
Grade 3
(stridor, respiratory distress)
Grade 4
(severe compromission, 
tracheotomy)
Laryngeal oedema* 10/56
(18%)
0/56
-
0/56
-
2/56
(3%)
Grade 1
(light)
Grade 2
(moderate)
Grade 3
(severe)
Grade 4
(disabling)
Pain* 10/56
(18%)
5/56
(9%)
0/56
-
0/56
-
Grade 1
(flushing, or transient rash, 
fever < 38°)
Grade 2
(flushing, rash or orticaria, 
fever = 38°)
Grade 3
(bronchospasm with or 
without orticaria)
Grade 4
(anaphylaxis)
Allergic reactions* 1/56
(2%)
2/56
(3%)
0/56
-
0/56
-
Grade 1
(loss of appetite)
Grade 2
(lower caloric intake without 
weight loss)
Grade 3
(weight loss requiring 
enteral/parenteral nutrition)
Grade 4
(life-threatening 
denutrition)
Nausea* 13/56
(23%)
0/56
-
0/56
-
0/56
-
Grade 1
(no treatment required)
Grade 2
(necessity of brief liquid i.v 
infusion)
Grade 3
(necessity of continuative 
treatment > 24 h)
Grade 4
(shock)
Hypotension* 1/56
(2%)
2/56
(3%)
0/56
-
0/56
-
Grade 1 Grade 2
Alopecia* 2/56
(3%)
0/56
-BMC Cancer 2009, 9:313 http://www.biomedcentral.com/1471-2407/9/313
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CRT is feasible and can be easily reproduced, with mini-
mal procedural complications [6].
We chose carboplatin and its dosage in view of the efficacy
of its anti-tumoral activity demonstrated in our previous
reports [13-15]. The dose of 350 mg/m2 was comparable
to the cisplatin "decadoses" used by Robbins et al.
[3,9,20-22], without relying on supportive measures to
alleviate cisplatinum-related toxicities.
Compared with our previous neo-adjuvant intra-arterial
carboplatin protocol [15], systemic toxicity of concurrent
intra-arterial carboplatin administration and 3D CRT was
usually mild to moderate; in fact, 11 (20%) patients did
not complete the four cycles of chemotherapy due to the
Immediate post-treatment response Figure 2
Immediate post-treatment response. CR = complete 
response; NR = no response.
45 (80%) 
Completed protocol 
56 patients 
11 (20%) 
Not completed protocol 
10 CR (90%)  1 NR (10%)  44 CR (98%)  1 NR (2%) 
54 CR (96%) 
Follow-up Figure 3
Follow-up. CR = complete response; NR = no response; NED = no evidence of disease; DOD = died of other disease; 
DWD= died with disease; T = tumour; N = neck; M = Metastasis; CHT = chemotherapy; S = surgery; AWD = alive with dis-
ease.
56 patients 
54 CR  2 NR 
2 DWD 14 recurrences 1 DOD 40 NED
1 second T  2 T and N  1 T and M  5 on T  1 N and M  4 M 
Palliative Palliative  Palliative  CHT
CHT CHT  treatment 
1 DWD  2 DWD  1 DWD  1 DWD  4 DWD 
2 Palliative  2 S  1 AWD 
CHT
1 NED  1 recurrence  2 DWD 
1 DWD BMC Cancer 2009, 9:313 http://www.biomedcentral.com/1471-2407/9/313
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appearance of haematological toxicity, involving all three
blood-cell lines, platelets, leukocytes and red blood cells.
In particular, severe thrombocytopenia was the factor
which mostly limited intra-arterial infusion owing to the
high risk of haemorrage during the Seldinger procedure.
Local toxicity also occurred frequently, mainly affecting
the skin and oral mucosa, requiring tracheotomy in 2
patients, nasogastric tube feeding in 1 patient and PEG in
another 3 patients.
These results are similar to those presented by other
authors who used significantly lower doses of carboplatin
[10,11] and suggest that carboplatin dose-increase does
not worsen toxic effects. For this reason, we believe that
carboplatin could be used as an alternative to cisplatin in
RADPLAT mimicking protocols [12], instead of perform-
ing a less intensive RADPLAT treatment, as proposed by
Yoshizaki et al. [8].
Even though the results of all the concurrent chemoradio-
therapy trials are difficult to compare due to differences
regarding dose, timing of intra-arterial infusion and dura-
tion of follow-up [5-7,23,24], our study confirmed that
the percentage of post-treatment complete response is
very high (96%) (table 6) and superior to induction intra-
arterial chemotherapy protocols [15,25,26].
However, part of the impressive effect of this kind of pro-
tocol could be due also to the fact that 12 of the 56
patients (21%) were in limited stage II.
This therapeutic regimen also has impressive organ pres-
ervation capabilities [1,12] as confirmed by 97.5% of our
NED patients in whom the tumour site was preserved.
Our two-year overall survival rate of 75% was comparable
to that observed in other RADPLAT protocols with the
same follow-up period [8,12]. As pointed out by other
authors [1,27-29], N stage and the recurrence of the dis-
ease were the most important factors influencing overall
survival. In fact, all our patients in whom neck disease
recurred or who developed distant metastases had clini-
cally positive necks at the time of diagnosis. For this rea-
Overall survival Figure 4
Overall survival.
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Overall survival according to neck status Figure 5
Overall survival according to neck status.
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Overall survival according to recurrence Figure 6
Overall survival according to recurrence.
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Disease free survival.
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son, many authors suggest planning neck dissection in N+
patients submitted to concurrent intra-arterial chemoradi-
otherapy [1,30-32].
Surprisingly, we found that another factor conditioning
survival was gender. We are unable to explain this evi-
dence; genetic factors may influence the biological
response of the tumour to treatment, or male patients may
keep up habits that can influence recurrence of the dis-
ease, such as smoking and alcohol consumption.
The Kaplan-Meyer estimate of two-year disease free sur-
vival was 69%. Recurrence and death due to the disease
occurred within the first 24 months after treatment; for
this reason we recommend a more thorough follow-up
during this period so that appropriate treatment can be
implemented as soon as possible, even though the results
of salvage surgery and/or systemic chemotherapy are
often frustrating.
Also in the case of disease-free survival, all the patients in
whom disease recurred were males. The explanation may
be the same as for overall survival. Unfortunately, there
are no data in the literature that help to explain this phe-
nomenon.
Regarding the role of haematological stimulating factors
in conditioning survival, even if randomized trials have
demonstrated that they can have a negative impact on
prognosis in patients with HNSCC submitted to chemo-
radiotherapy [33,34], our study didn't give definitive
results because only 2 patients were treated with these
compounds and 1 is disease-free and the other died for
disease. For this reason, the use of growth factors during
radiochemotherapy is questionable and their possible
negative effect must be taken into consideration when
analizing survival of this kind of treatment protocols.
Conclusion
Intra-arterial carboplatin administration with concurrent
three-dimensional conformal radiation therapy seems to
be an effective treatment of advanced head neck tumours
at least in a short time of follow-up. Moreover, the haema-
tological and non-haematological toxicities virtually sim-
ilar to the RADPLAT protocol, render carboplatin a valid
alternative because it has the advantage of not being
nephrotoxic and being used at very high doses without
any significant increase in the entity of side effects.
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